In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Abstract: It is challenging to extend the support region of state-of-the-art local edge-preserving filtering approaches to the entire input image on account of huge memory cost and heavy computational ...

Innovation fails when every pilot starts from scratch; the chassis approach shows how to move fast with vendors while keeping ...

Quiet backlist titles with lasting emotional pull and literary strength, proving relevance does not fade with age or ...

C compiler, LustreC, into a generator of both executable code and associated specification. Model-based design tools are ...

Abstract: An algorithm for simultaneous identification of unknown time delays and parameters of interconnected discrete-time delay multivariable systems is proposed in this paper. This algorithm ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Casey Murphy has fanned his passion for finance through years of writing about active trading, technical analysis, market commentary, exchange-traded funds (ETFs), commodities, futures, options, and ...